The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Issue 3 (4th March 2018)

• Record Type: Journal Article
• Authors: Corona, G.; Rastrelli, G.; Reisman, Y.; Sforza, A.; Maggi, M.
• Is Part Of: Expert opinion on drug safety. Volume 17:Issue 3(2018)
• Page Start: 277
• Page End: 292
• Publication Date: 2018-03-04
• Subjects: Testosterone treatment -- late onset hypogonadism -- cardiovascular risk -- prostate safety -- gonadotropins; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2018.1424831
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : In the case of primary male hypogonadism (HG), only testosterone (T) replacement therapy (TRT) is possible whereas when the problem is secondary to a pituitary or hypothalamus alteration both T production and fertility can be, theoretically, restored. We here systematically reviewed and discussed the advantages and limits of medications formally approved for the treatment of HG. Areas covered : Data derived from available meta-analyses of placebo controlled randomized trials (RCTs) were considered and analyzed. Gonadotropins are well-toleratedand their use is mainly limited by higher costs and a more cumbersome treatment schedule than TRT. Available RCTs on TRT suggest that cardiovascular (CV) and venous thromboembolism risk is not a major issue and that prostate safety is guaranteed. The risk of increased hematocrit is mainly limited to the use of short terminjectable preparations. Expert opinion : In the last few years the concept of 'organic' irreversible HG and 'functional' or age- and comorbidity-related HG has been introduced. This definition is not evidence-based. The majority of RCTs enrolled patients with 'functional' HG. Considering the significant improvement in body composition, glucose metabolism and sexual activity, TRT should not be limited to 'organic' HG, but also offered for 'functional'.